Immune checkpoint inhibitor-associated pituitary adverse events: an observational, retrospective, disproportionality study

ConclusionsICI-associated pituitary adverse events have significantly increased, and their clinical characteristics should be kept in mind by oncologists and endocrinologists who manage patients treated by immunotherapy.

http://link.springer.com/10.1007/s40618-020-01226-4

Source: Journal of Endocrinological Investigation - March 31, 2020 Category: Endocrinology Source Type: research